Delivering high value therapies in COPD: the secret is in the marketing. Issue 4 (25th April 2019)

• Record Type: Journal Article
• Authors: Ashdown, Helen; Steiner, Michael
• Is Part Of: European respiratory journal. Volume 53:Issue 4(2019)
• Publication Date: 2019-04-25
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00215-2019
• Languages: English
• ISSNs: 0903-1936

Abstract

There are a wide range of therapies now available for people suffering with chronic obstructive pulmonary disease (COPD), both pharmacological and non-pharmacological [1]. However, there has been recent recognition that non-pharmacological approaches (for example smoking cessation and pulmonary rehabilitation) deliver the highest value in terms of patient benefit in relation to cost [2]. It is also evident that the provision of high value therapies in clinical practice is frequently sub-optimal, as illustrated in figure 1 summarising data from a recent, comprehensive primary care audit of COPD care in Wales [3]. The importance of prioritising uptake of high value, non-pharmacological therapies in the management of COPD http://ow.ly/AA2u30ol4t5